Cmed Clinical Services

We deliver vital health information, at the time it matters.

High-tech company for innovative laboratory diagnostics and research services with strong focus on Rare Diseases and Newborn Screening. From Inborn Errors of Metabolism to Oncology we make personalized diagnostics more accessible.
We provide everything from routine tests to clinical studies and from biochemical to genetic testing.
We are dedicated to the development of novel laboratory tests that make actionable health information fast accessible.

Clinical Mass Spectrometry, Next-Generation Sequencing and development of novel assays and biomarkers for routine services and clinical research.
International Diagnostic Services for Biotech & Pharma companies.
ARCHIMEDlife Research Institute for academic research, - omics and biomarker discovery.

F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients with cancer greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating best-in-class drug candidates with broad therapeutic index and monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for patients with cancer.

Asper Biogene is a genetic testing company focused on diagnostics of hereditary diseases. Medical specialities such as ophthalmology, neurology, cardiology, oncology etc are assembled into various testing portfolios. The portfolios consist of comprehensive variety of testing options with different diagnostic strategies, from single gene analysis to whole genome sequencing.

In addition to ready-to-use tests, we develop and implement custom-made tests and solutions in order to meet the specific needs of the health care providers.

#genetictesting #diagnostics #NGSpanels

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics.

Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation, infectious diseases, biofilm culture, stem cell research, sickle cell disease, asthma, and allergies. Our Microfluidic Solutions include set-ups for droplet generation, organ-on-chip and VOC analysis.

More recently, Cellix's multi-disciplinary team of engineers and scientists have been developing our Inish Solutions range: microfluidic label-free impedance cell analysis and sorting. We want our customers to succeed so we are demystifying flow cytometry and bringing them simple, easy-to-use cell analysis and sorting for every lab, not just core facilities.